Healthcare provider profile · identity verified

Asia E Lo, DPM

Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · HOUSTON, TX · NPI 1386625812

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Asia E Lo, DPM received $4,874.21 in general payments during 2025 across 61 reported records.

ETS Wound Care LLC accounted for 35.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 31 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$4,874.21

61 reported records · 20 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ETS Wound Care LLC Unresolved — no canonical attribution shown $1,747.8335.9%92025
Trimed, Inc. Unresolved — no canonical attribution shown $1,155.6323.7%52025
Stryker Corporation Unresolved — no canonical attribution shown $505.3910.4%92025
RedDress USA, Inc. Unresolved — no canonical attribution shown $340.637.0%12025
TREACE MEDICAL CONCEPTS, INC. Unresolved — no canonical attribution shown $159.903.3%62025
restor3d, inc. Unresolved — no canonical attribution shown $145.463.0%22025
Paratek Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $141.212.9%82025
Smith+Nephew, Inc. Unresolved — no canonical attribution shown $138.892.9%42025
AXOGEN Unresolved — no canonical attribution shown $126.252.6%12025
MIMEDX Group, Inc. Unresolved — no canonical attribution shown $113.002.3%42025
Fusion Orthopedics USA, LLC Unresolved — no canonical attribution shown $64.341.3%12025
Abbott Laboratories Unresolved — no canonical attribution shown $44.080.9%22025
Globus Medical, Inc. Unresolved — no canonical attribution shown $37.880.8%12025
ANI Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $29.740.6%12025
Urgo Medical North America, LLC Unresolved — no canonical attribution shown $29.210.6%12025
Acera Surgical, Inc. Unresolved — no canonical attribution shown $27.850.6%12025
Bone Support Inc. Unresolved — no canonical attribution shown $20.780.4%12025
Solventum Corporation Unresolved — no canonical attribution shown $17.500.4%12025
Next Science LLC Unresolved — no canonical attribution shown $14.630.3%12025
Kerecis Limited Unresolved — no canonical attribution shown $14.010.3%22025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$3,225.4655
Travel and Lodging$970.552
Education$678.204

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
MIRRAGEN ADVANCED WOUND MATRIX
Normalized: mirragen advanced wound matrix
Device ETS Wound Care LLC $1,747.83 9 2025
Source payment records
Tools - AFS
Normalized: tools afs
Device Trimed, Inc. $824.12 1 2025
Source payment records
ActiGraft
Normalized: actigraft
Device RedDress USA, Inc. $340.63 1 2025
Source payment records
AUGMENT INJECTABLE
Normalized: augment injectable
Device Stryker Corporation $219.94 4 2025
Source payment records
Tools - WFS
Normalized: tools wfs
Device Trimed, Inc. $186.28 1 2025
Source payment records
CT THROMBECTOMY SYSTEM KIT
Normalized: ct thrombectomy system kit
Device Stryker Corporation $157.77 2 2025
Source payment records
FLOWTRIEVER CATHETER, S
Normalized: flowtriever catheter s
Device Stryker Corporation $157.77 2 2025
Source payment records
NUZYRA
Normalized: nuzyra
Drug Paratek Pharmaceuticals, Inc. $141.21 8 2025
Source payment records
VARIAX
Normalized: variax
Device Stryker Corporation $95.68 2 2025
Source payment records
TMC NANOPLASTY SYSTEM
Normalized: tmc nanoplasty system
Device TREACE MEDICAL CONCEPTS, INC. $78.34 3 2025
Source payment records
FLEXBAND PLUS
Normalized: flexband plus
Device Stryker Corporation $72.94 1 2025
Source payment records
GRAFIX PL
Normalized: grafix pl
Biological Smith+Nephew, Inc. $63.79 1 2025
Source payment records
HOFFMANN
Normalized: hoffmann
Device Stryker Corporation $53.82 2 2025
Source payment records
EASYFUSE
Normalized: easyfuse
Device Stryker Corporation $47.38 1 2025
Source payment records
FLEXBAND
Normalized: flexband
Device Stryker Corporation $47.38 1 2025
Source payment records
ETERNA
Normalized: eterna
Device Abbott Laboratories $44.08 2 2025
Source payment records
COLLAGENASE SANTYL
Normalized: collagenase santyl
Drug Smith+Nephew, Inc. $41.55 2 2025
Source payment records
ANTHEM
Normalized: anthem
Device Globus Medical, Inc. $37.88 1 2025
Source payment records
RENASYS TOUCH
Normalized: renasys touch
Device Smith+Nephew, Inc. $33.55 1 2025
Source payment records
PURIFIED CORTROPHIN GEL
Normalized: purified cortrophin gel
Drug ANI Pharmaceuticals, Inc. $29.74 1 2025
Source payment records
VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP
Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap
Device Urgo Medical North America, LLC $29.21 1 2025
Source payment records
Restrata Wound Matrix
Normalized: restrata wound matrix
Device Acera Surgical, Inc. $27.85 1 2025
Source payment records
REGRANEX
Normalized: regranex
Drug Smith+Nephew, Inc. $22.97 1 2025
Source payment records
CERAMENT G
Normalized: cerament g
Device Bone Support Inc. $20.78 1 2025
Source payment records
CERAMENTBONE VOID FILLER
Normalized: ceramentbone void filler
Device Bone Support Inc. $20.78 1 2025
Source payment records
ACTIV.A.C.
Normalized: activ a c
Device Solventum Corporation $17.50 1 2025
Source payment records
PROMOGRAN PRISMA
Normalized: promogran prisma
Device Solventum Corporation $17.50 1 2025
Source payment records
BlastX
Normalized: blastx
Device Next Science LLC $14.63 1 2025
Source payment records
Xperience
Normalized: xperience
Device Next Science LLC $14.63 1 2025
Source payment records
Kerecis GraftGuide
Normalized: kerecis graftguide
Device Kerecis Limited $14.01 2 2025
Source payment records
Kerecis SurgiClose
Normalized: kerecis surgiclose
Device Kerecis Limited $14.01 2 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Ammonium LactateAmmonium Lactate3620
CiclopiroxCiclopirox3415
ClotrimazoleClotrimazole3217
LevofloxacinLevofloxacin1613
Terbinafine HclTerbinafine Hcl14suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim1211

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $4,874.21 · 61 records ETS Wound Care LLC ACTIV.A.C., ANTHEM, AUGMENT INJECTABLE, ActiGraft, BlastX, CERAMENT G, CERAMENTBONE VOID FILLER, COLLAGENASE SANTYL, CT THROMBECTOMY SYSTEM KIT, EASYFUSE, ETERNA, FLEXBAND, FLEXBAND PLUS, FLOWTRIEVER CATHETER, S, GRAFIX PL, HOFFMANN, Kerecis GraftGuide, Kerecis SurgiClose, MIRRAGEN ADVANCED WOUND MATRIX, NUZYRA, PROMOGRAN PRISMA, PURIFIED CORTROPHIN GEL, REGRANEX, RENASYS TOUCH, Restrata Wound Matrix, TMC NANOPLASTY SYSTEM, Tools - AFS, Tools - WFS, VARIAX, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, Xperience
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error